
Xuelin Huang
Articles
-
Nov 13, 2024 |
nature.com | Vera Adema |Kelly S. Chien |Sanam Loghavi |Feiyang Ma |Guillermo Montalban-Bravo |Xuelin Huang | +1 more
AbstractIn myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells’ (HSPCs’) aberrant differentiation towards the myeloid lineage at the expense of erythropoiesis.
-
Nov 13, 2024 |
nature.com | Vera Adema |Kelly S. Chien |Sanam Loghavi |Feiyang Ma |Guillermo Montalban-Bravo |Xuelin Huang | +1 more
AbstractIn myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells’ (HSPCs’) aberrant differentiation towards the myeloid lineage at the expense of erythropoiesis.
-
Sep 25, 2024 |
nature.com | Farhad Ravandi |Jayastu Senapati |Nicholas Short |Tapan M Kadia |Gautam Borthakur |Marina Konopleva | +5 more
AbstractOptimal frontline use of active agents in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is prudent to improve outcomes. We report the long-term follow-up of the phase 2 trial of HyperCVAD with nelarabine and pegylated asparaginase (Original cohort). In the latest protocol iteration venetoclax was added to the induction/consolidation regimen (Venetoclax cohort). Eligible patients were adults with untreated T-ALL/LBL or after minimal therapy and with adequate organ function.
-
Aug 18, 2023 |
biorxiv.org | Yizhuo Wang |Xuelin Huang |Ziyi Li |Michael Wang
AbstractSingle-cell RNA sequencing (scRNA-seq) technology has been widely used to study the differences in gene expression at the single cell level, providing insights into the research of cell development, differentiation, and functional heterogeneity. Various pipelines and workflows of scRNA-seq analysis have been developed but few considered multi-timepoint data specifically.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →